VIETNAM VETERANS WITH DIABETES

Vietnam Veterans with Diabetes, Diabetes, Vietnam, Veterans

News

FALL

Posted by Randall W Brown on September 24, 2012 at 6:50 AM Comments comments (0)

It is Fall now. Have you gotten your Flu shot??

study shows 36% Weight Loss

Posted by Randall W Brown on May 26, 2012 at 8:20 AM Comments comments (0)

One Year Study Showed a 36% Loss in Excess Body Weight

Obese individuals completed a 1-year study and lost a mean 35.6% of excess body weight taking….

 

Advertisement Patients taking 3 mg of liraglutide daily lost a mean 35.6% of body weight.Nick Finer, MBBS, consultant endocrinologist and bariatric physician at University College London Hospitals (UCLH) and UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery at University College London, United Kingdom, reported that, the number needed to treat (NNT) to achieve a loss of 10% of total body weight was only 3 mg.

Dr. Finer described a 20-week trial extended to 52 weeks in which participants with a body mass index (BMI) of 30 to 40 kg/m2, aged 18-65 years, and with a fasting plasma glucose level less than 7.0 mmol/L (126 mg/dL) underwent a placebo run-in for 2 weeks and were then randomly assigned to 1 of 6 treatment groups: subcutaneous liraglutide at 1.2 mg/day, 1.8 mg/day, 2.4 mg/day, or 3.0 mg/day; subcutaneous placebo injection; or oral orlistat, 120 mg 3 times per day.

From weeks 20 to 52, the investigators and participants were blinded to liraglutide or placebo treatment. Throughout the trial, participants were on a diet providing a 500-kcal/day deficit and had increased physical activity.

In a post hoc analysis, the investigators explored the percentage of weight loss at 52 weeks in responders who achieved a 5% or greater weight loss at 12 weeks, as well as the percentage of excess body weight loss (EBWL) at 52 weeks with liraglutide.

All the groups (n = 90-98 per group) were well matched for baseline characteristics and differed little at baseline for individuals who completed 52 weeks. They were about 1 quarter male, aged 45 to 47 years, with body weight of 96.0 to 98.4 kg, BMI of 34.1 to 35.0 kg/m2, and excess body weight of 34.8 to 38.4 kg. Excess body weight is that amount in excess of having a calculated BMI of 25 kg/m2.

Across all the groups, a total of 356 participants completed 52 weeks.

Weight loss at 20 weeks continued out to 52 weeks in a dose-dependent manner for liraglutide. "You can see that orlistat patients did lose weight but were about equivalent to the lowest dose, the 1.2 mg of liraglutide, and about half that seen for the higher doses of liraglutide," Dr. Finer reported.

Patients who achieved at least a 5% weight loss at 12 weeks were considered responders, and that included 75% of people receiving 3.0 mg of liraglutide per day and 32% of those receiving placebo. The placebo responder group lost 7.1 kg by 52 weeks.

The highest-dose liraglutide nonresponders had lost only 3.4 kg at 12 weeks "but in fact continued to lose weight out to 1 year -- 6 kilos -- so one might argue these were not truly non-responders," Dr. Finer said.

Liraglutide responders had lost 7.9 kg at 12 weeks and by 52 weeks had lost 11.1 kg, which was a total body weight loss of nearly 12%.

Only 38% of the orlistat group were responders. "In terms of the ultimate weight loss in the responders' group, there was not a large difference between orlistat and liraglutide," D. Finer said. "If you did respond to orlistat, you did well. It was just you were much less likely to respond."

Increasing liraglutide doses were associated with increasing amounts of EBWL; a 35.6% EBWL was seen with the 3.0-mg dose, which is the dose being carried forward in further weight loss trials.

No one who completed 52 weeks of treatment with liraglutide, 3.0 mg, gained weight, but 27% of those receiving placebo and 13% of those taking orlistat did.

"I would like to emphasize that liraglutide is not licensed as a weight loss agent at this stage and has not completed its safety trials let alone its long-term efficacy trials in phase 3 trials," Dr. Finer cautioned the audience.

In an intention-to-treat analysis, the NNT to achieve a 5% weight loss at 1 year was 2 for liraglutide, 3.0 mg; 3 for orlistat; and 4 for placebo. To achieve a 10% weight loss, the NNTs were 3, 7, and 10, respectively. "I think that we should be encouraged by these data," Dr. Finer said. "I think there's often a lot of negativity, but an NNT of 3 [for liraglutide] for a 5% weight loss is really quite impressive."

Dr. Finer said the 35% EBWL with liraglutide stacks up favorably against the findings seen with bariatric surgery. "The use of excess body weight loss and also, I should say, numbers needed to treat, I think give clearly defined weight loss targets and perhaps a more optimistic interpretation of these data," he concluded.

Luca Busetto, MD, from the Department of Medical and Surgical Sciences and a member of the Obesity Center at the University of Padova in Padova, Italy, commented that newer, effective antiobesity drugs may in the future be the most appropriate treatment for people with class 1 obesity.

"Probably the potency of these new drugs will be sufficient enough in order to solve the problem," he said. "So I think that we will not need surgery any more in patients with BMI between 30 to 35 [kg/m2], and probably also in the BMI class 35 to 40 [kg/m2] we may have some competition between drugs and surgery, at least less invasive surgery." For larger patients, Dr. Busetto thinks that surgery will remain the most efficacious therapy for at least the next 5 to 10 years.

For patients who can be managed with drugs, he thinks therapy will probably have to be life-long, although long-term data are lacking. "Obesity is a chronic disease, and probably we need to think of treating obesity as we treat hypertension, as we treat type 2 diabetes," Dr. Busetto said.

But as with other chronic medications, adherence may be a problem, especially with an injectable drug such as liraglutide, although development of longer-acting GLP-1 analogues that require less frequent injections may help.

Dr. Busetto predicted that liraglutide for weight loss may face some regulatory hurdles both in the United States and in Europe because licensing agencies may require not only demonstration of efficacy for weight loss but also demonstration of cardiovascular safety, "probably as a consequence of the problem with sibutramine in the past."

Dr. Finer has been an advisory board member and done paid lecturing and commercially sponsored research for Novo Nordisk A/S. He has also received lecture and consultancy fees from Roche in the past. The study was funded by Novo Nordisk A/S. Dr. Busetto has disclosed no relevant financial relationships.

19th European Congress on Obesity (ECO). Abstract #152. Presented May 11, 2012.

 

 

 

Related Articles

Appetite-curbing Hormone Helps to Lose Weight

GLP-1 Help to Control Diabetes after Gastric Bypass

EASD: Liraglutide Plus Insulin Does Not Add Weight

LOW CARBS FOR JUST TWO DAYS SPURS WEIGHT LOSS

Posted by Randall W Brown on March 15, 2012 at 8:20 AM Comments comments (0)

Low Carbs for Just Two Days a Week Spurs Weight Loss

Adhering to a strict, low-carbohydrate diet two days per week led to greater reductions in weight and insulin levels when compared with standard daily dieting....

 

Advertisement Can you diet for just two days a week? You might be able to drop more weight if you cut back on carbs just two days a week.

British researchers found that women who essentially gave up carbs for two days and ate normally the rest of the time dropped about 9 pounds on average, as compared to the 5 pounds lost by women who cut back to around 1,500 calories every day, according to a new report presented at the CTRC-AACR San Antonio Breast Cancer Symposium.

The study's lead author Michelle Harvie, a research dietician at the Genesis Prevention Center at the University Hospital in South Manchester, England stated that, "We came up with the idea of an intermittent low-carb diet because it enables people to still have foods that are very satiating." "Also, there's a lot of evidence from other studies showing that restricting carbohydrates has the same effect as restricting energy."

Harvie and her colleagues were spurred to find a diet that would be easier for women to follow because research has shown that obesity and the changes it causes in the body increase the risk for breast cancer. "We know from our research in animal models that losing weight has the potential for reducing breast cancer risk," Harvie said.

The researchers followed 88 women for four months. All the women were at high risk for breast cancer based on their family histories. One third of the women were put on a Mediterranean-type diet that restricted calories to about 1,500 per day. A second group was told to eat normally most of the time, but two days a week to cut carbs and also calories to about 650 on those two days. The third group was also to cut carbs two days a week, but there was no calorie restriction on those days.

At the end of four weeks women in both of the intermittent dieting groups had lost more weight -- about 9 pounds -- than the women who ate low calorie meals every day of the week -- about 5 pounds.

Women in the intermittent dieting groups also had better improvement than daily dieters in the levels of hormones -- insulin and leptin -- that have been linked with breast cancer risk, Harvie said. And, yes, this is something you can try at home, Harvie said. You just need to dramatically cut back carbohydrates two days a week and try to eat sensibly the rest of the time, she added.

What that means, Harvie said, is that you can eat protein and healthy fats on the two low carb days, but skip bread, pasta, root vegetables like potatoes, carrots and parsnips to get to the 50g limit. The diet allows for one piece of fruit on the low carb days. Other foods on the menu include: nuts and green, leafy vegetables, peppers, mushrooms, tomatoes, broccoli, eggplant and cauliflower.

Presented at the CTRC-AACR San Antonio Breast Cancer Symposium Nov. 2011

 

 

 

Grilled Salmon Salad of Love

Posted by Randall W Brown on November 29, 2011 at 7:55 AM Comments comments (0)

This is from Chef Robert Lewis. He is the Happy Diabetic Chef. I know Robert and his love and touch for food is great.

Grilled Salmon Salad of Love

Ingredients

Salmon:

2 tablespoons soy sauce

1 tablespoon honey

1 tablespoon lemon juice

Zest of 1 lemon

1/4 teaspoon ground ginger

4 5 ounce (150 g) skinless salmon fillets

Lemon Dressing:

1 tablespoon lemon juice

1 tablespoon olive oil

1 tablespoon white wine vinegar

1/8 teaspoon sugar

Salt and pepper to taste

Salad:

3 cups baby spinach

1 ripe avocado, peeled, pitted, diced

1 ripe mango, peeled, pitted, diced

2 tablespoons finely chopped red onion

2 tablespoons capers

 

Get Happy, Get Healthy

 

Simply Desserts

 

Signature Seasoning Pack